1. Generics Bulletin
  2. >>Products
  3. >>Generics

Endo’s Par Opts For Authorized Generic As It Debuts Lubiprostone In US

Multiple ANDA Sponsors Waiting In The Wings

 
• By Dean Rudge

Endo’s Par has introduced the first generic version of Mallinckrodt’s chronic idiopathic constipation medicine Amitiza, realizing the terms of a settlement agreement announced more than six years ago.

Racing
Endo's Par has a settlement that put it years ahead of ANDA rivals. • Source: Shutterstock

Endo’sPar Pharmaceutical unit has introduced the first generic version of Mallinckrodt’s Amitiza (lubiprostone) 8mcg and 24mcg soft gel capsules in the US, an authorized generic, years ahead of several potential abbreviated new drug application rivals.

More than six years ago, before Endo acquired Par and Mallinckrodt acquired Amitiza developer Sucampo, Par and its Anchen Pharmaceuticals...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Bio-Thera Matches Alvotech With US Golimumab Filing Acceptance

 
• By Dean Rudge

Bio-Thera is one step closer to launching a biosimilar to Johnson & Johnson’s Simponi in the US, following FDA acceptance of its BAT2506 proposed golimumab candidate.

Samsung Bioepis Finds New US Partner For Ophthalmic Biosimilars

 
• By Dave Wallace

Samsung Bioepis has announced a fresh ophthalmic biosimilars partnership with Harrow, as the end approaches for a longstanding US commercialization alliance with Biogen on the Korean firm's Lucentis (ranibizumab) and Eylea (aflibercept) rivals Byooviz and Opuviz.

‘Our Position Has Naturally Shifted’ – How Standalone Sandoz Is Taking On Originator Abuses

 
• By Dave Wallace

As a standalone generics and biosimilars company, Sandoz now feels freer to speak out against originator abuses of intellectual property, the firm’s global IP head Julia Pike tells Generics Bulletin, including challenges to Bayer on rivaroxaban and Amgen on etanercept.